Kura Oncology's Upcoming Investor Conference Engagements
Based in San Diego, Kura Oncology, Inc. (Nasdaq: KURA) is a pioneering biopharmaceutical company devoted to creating precision medicines specifically for cancer treatment. The company has announced its participation in a series of important investor conferences aimed at fostering dialogue and engagement with investors.
Participation in Notable Conferences
TD Cowen 6th Annual Oncology Innovation Summit
Kura's management team is set to engage in a fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit, scheduled to occur virtually on May 27, 2025. This conference is a significant platform for discussing innovative oncology treatments and networking with industry leaders.
Jefferies Global Healthcare Conference
Following that, they will present at the renowned Jefferies Global Healthcare Conference in New York City on June 4, 2025. This event gathers key stakeholders in the healthcare sector, offering insights into the latest advancements and investment opportunities.
Goldman Sachs Annual Global Healthcare Conference
Kura will also partake in the Goldman Sachs Annual Global Healthcare Conference in Miami on June 10, 2025. These conferences are vital for not only sharing pivotal updates about their pipeline and progress but also for obtaining valuable feedback from investors.
Live Webcasts and Archived Presentations
For those interested in following these events, live audio webcasts will be accessible via Kura's dedicated Investors section on their website. Moreover, attendees can look forward to archived presentations following each conference, ensuring accessibility to important discussions and insights.
About Kura Oncology and Their Innovative Pipeline
Kura Oncology is at the forefront of developing targeted therapies for cancer through their progressive pipeline of small molecule drug candidates. One of their flagship drugs, Ziftomenib, is the first investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for treating relapsed or refractory NPM1-mutant acute myeloid leukemia (AML).
In late 2024, Kura entered a global strategic collaboration with Kyowa Kirin Co., Ltd. to further the development and commercialization of Ziftomenib for AML and other hematologic cancers. The completion of enrollment in the KOMET-001 trial marks a significant milestone, as the organization prepares to submit a New Drug Application to the FDA for adult patients suffering from this specific type of leukemia.
In addition to Ziftomenib, Kura is investigating KO-2806, a next-generation farnesyl transferase inhibitor (FTI), currently being evaluated in a Phase 1 trial for various solid tumors. Furthermore, Tipifarnib is undergoing trials in combination with other therapies to assess its effectiveness in head and neck squamous cell carcinoma.
Stay Informed with Kura Oncology
For more information on Kura’s initiatives, including their robust pipeline and ongoing clinical trials, be sure to visit their website. Stay connected with their latest news and updates by following Kura on X and LinkedIn.
Contact Information
For questions or further inquiries, investors can reach out to Patti Bank, Managing Director, at (415) 513-1284 or via email at patti.bank@icrhealthcare.com. Media inquiries can be directed to media@kuraoncology.com.
Frequently Asked Questions
What is Kura Oncology known for?
Kura Oncology specializes in developing precision medicines for cancer treatment, focusing on innovative therapies.
When will Kura participate in investor conferences?
Kura is scheduled to participate in three significant investor conferences throughout late May and early June 2025.
What is Ziftomenib?
Ziftomenib is a leading investigational therapy from Kura Oncology targeted at treating AML, with Breakthrough Therapy Designation from the FDA.
How can I follow Kura Oncology's updates?
You can stay informed about Kura's news and developments by visiting their official website and following them on social media platforms.
Who can I contact for more information?
Investors can contact Patti Bank for queries, while media inquiries should be directed to Kura's media email.
